Where Manoj Bhatia, CA-AM, senior product marketing

New Post Public Reply Private Reply Replies (0) Message Board
patientgal

Where Manoj Bhatia, CA-AM, senior product marketing manager of go-to-market strategy for the midmarket at Cisco, covered “David-Goliath” partnerships as they relate to the tech industry, Pannie Trifillis, Ph.D., CA-AM, director of alliance management at PTC Therapeutics, and Christophe Sarry, CA-AM, global alliance director at F. Hoffman–La Roche, tackled the issue from the pharma perspective in one of the final sessions of last week’s 2013 ASAP Global Alliance Summit in their presentation “Does Size Matter?: Handled Skillfully, Alliances Between Small and Large Companies Can Reap Big Benefits for Both.”

PTC and Roche are currently working together on two major collaborations. A few years ago, they first engaged around GEMS (Gene Expression Modulation by Small Molecules) technology. They formed a second initiative—one of the 2013 Alliance Excellence Awards runner-ups in the Individual Alliance category—dubbed the Spinal Muscular Atrophy (SMA) alliance in which the two companies have teamed up with the Spinal Muscular Atrophy Foundation to find a cure to a devastating disease that takes the lives of thousands of infants each year.

The two companies make for an interesting contrast. In the wake of its acquisition of Genentech, Roche now essentially has two large R&D organizations to manage. Contrast that to PTC, which has fewer employees (125) than Roche has partners (more than 150).

As the session title might suggest, you got the sense from both Trifillis and Sarry that the answer to the posed question is that the relative sizes of a biotech and a Global 1,000 drug manufacturer end up dictating the roles each plays in an alliance primarily, not the power dynamics of the relationship. The two scientists fittingly opened with a nature analogy to describe a “symbiosis” between the two entities; in the depths of our natural bodies of water, the cleaner shrimp species gets its nourishment by cleaning parasites, insects, algaes, and other matter off of the moray eel—the latter is essentially pampered with a bath, while the former enjoys a free meal.

Similarly, large pharmaceutical players and small biotechs have common goals: to originate new therapies, obtain regulatory approval, garner support from payers, be first to market, and maximize drug sales, according to Trifillis and Sarry.

This is not to say differences don’t exist. Small pharmaceutical companies are flexible, focused, nimble, have direct oversight from the company’s most senior management, and tend to be highly innovative. They also are limited financially as compared with their bigger brethren. On the other hand, big pharma has a significant wealth of available resources, and can reach high economies of scale with its global operations. Its large alliance portfolio enables an exchange of information across alliances and a high degree of learning internally.

Of course, with size comes a little more complexity and red tape, as processes must be set up to streamline operations. And, yes, these processes do impact the speed of decision making for an alliance.

“We can’t work without [these processes] as a large company,” said Sarry, who added that one of the primary challenges faced by the bigger organization is aligning resources and ensuring that they go to the right projects.

Trifillis saw one major benefit to the sharply distinct corporate cultures—the differences justify alliance management.

“We have a job,” she quipped.

Harnessing these differences brings great benefits to both sides. Biotechs provide large pharmaceutical companies: 1) early drug discovery capability, 2) specialized expertise (e.g., orphan drugs), 3) flexibility and faster decision making, which can help advance a program far more quickly than a large pharmaceutical company ever could, and an 4) innovative and entrepreneurial atmosphere.

A company like Roche brings to PTC a high degree of cost- and risk-sharing. With its abundant resources, Roche can leverage technology for new therapeutic areas and maximize the smaller partner’s expertise (particularly in expensive areas like cardiology and oncology which might be out of the smaller entity’s reach). On the commercial end of the drug development cycle, the large pharmaceutical’s existing sales and marketing engines can help drive the biotech’s drug to success in the marketplace. If nothing else, a larger company’s involvement offers validation of the smaller organization’s research.

The keys to making these types of relationships work? It all comes down to respect and trust, said the presenters. Know what is important to the partner, define the needs of the alliance up front, establish criteria for success early, manage resources skillfully, and maintain transparency while keeping an eye on common goals along the way.

Sarry said that it is crucial to be proactive and detail the large company’s formal processes in the alliance’s start-up phase, long before the biotech is confronted with a situation that involves cutting through rolls of red tape. Trifillis agreed.

“If expectations are set up front that it will take this much time, we can live with it,” she said.

In the bigger picture, a strong relationship has many benefits, even if a compound never reaches the market. You never know when you may need that partner again down the road. Laws of karma are certainly at play, so both sides have plenty of incentive to play nice.

“Drugs die, but relationships last,” said Trifillis.

--John Lovietes

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 47

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 103

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 86

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 39

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 66

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 62

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 35

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 0

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 32

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Shifting Landscape of European Credit Markets

Updated Category News Views 140

Understanding European Credit Markets In recent discussions, many have highlighted the significant progress in European equities, which have surged to unprecedented highs due to several bullish factors. These include attractive valuations, supportive monetary policies, evolving geopolitical conditions, and vital reforms. Similar Trends in Credit Markets However, it's...

Continue Reading
Exploring the Daily Fund Prices of WisdomTree ETFs

Updated Category News Views 153

Understanding Net Asset Values in WisdomTree ETFs When you dive into investments, net asset value (NAV) becomes a crucial concept, particularly within exchange-traded funds (ETFs). WisdomTree, recognized for its wide variety of ETFs, shares daily updates on its fund prices. This information is vital for investors who want to make informed choices. These daily fund prices...

Continue Reading
Ryan Mueller of MLG Capital Honored as Multifamily Influencer

Updated Category News Views 270

Ryan Mueller Recognized as a Multifamily Influencer MLG Capital, a prominent name in private real estate investments, has announced that Ryan Mueller, the Principal and Senior Vice President, has earned recognition as a 2025 Influencer in Multifamily Real Estate by GlobeSt. This prestigious accolade highlights Ryan's exceptional contributions and leadership in the sphere...

Continue Reading
Ames Watson Steps In to Lead Champion Brand's New Era

Updated Category News Views 491

Ames Watson Takes Charge of Champion's Collegiate and Teamwear Divisions Ames Watson is set to drive significant growth and innovation for the renowned sportswear brand Champion. Following a recent acquisition by Authentic Brands Group, Ames Watson will steer Champion's storied collegiate apparel and teamwear operations. This partnership marks a strategic step in...

Continue Reading
TFA Logistics Expands Operations with Dillon Transportation Deal

Updated Category News Views 586

TFA Logistics Expands Operations with Dillon Transportation Deal TFA Logistics, a prominent freight and logistics solutions provider, has successfully completed the acquisition of the assets belonging to Dillon Transportation. This strategic move significantly enhances TFA's national operations and adds over 130 talented employees to its team. Strengthening the National...

Continue Reading